Paratek risk/reward favorable into Wednesday’s panel, says H.C. Wainwright

H.C. Wainwright analyst Ed Arce believes the risk/reward for Paratek Pharmaceuticals is “positively-skewed” into Wednesday’s FDA panel meeting for omadacycline. The analyst expects a “relatively smooth” panel and would be buyers of the stock heading into the early October FDA action date. Arce keeps a Buy rating on Paratek with a $55 price target.

https://bit.ly/2ASJhKW